Loading...
•
Sep 30, 2023
Castle Biosciences Q3 2023 Earnings Report
Reported a significant increase in revenue and test reports, driven by growth across its test portfolio, which led to positive earnings and operating cash flow. The company raised its full-year revenue guidance.
Key Takeaways
Castle Biosciences reported strong Q3 2023 results, with a 66% increase in revenue compared to Q3 2022, reaching $61.5 million. The company also saw a 52% increase in total test reports delivered. Due to consistent performance, Castle Biosciences raised its full year 2023 revenue guidance to at least $200 million.
Revenue increased by 66% to $61.5 million compared to Q3 2022.
Total test reports delivered increased by 52% compared to Q3 2022.
Net cash provided by operations was $5.0 million, compared to net cash used in operations of $5.2 million for the same period in 2022.
The company raised full year 2023 revenue guidance to at least $200 million from at least $180 million.
Forward Guidance
Castle Biosciences is increasing its guidance for anticipated total revenue in 2023. The Company now anticipates generating at least $200 million in total revenue in 2023 compared to the previously provided guidance of at least $180 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...